151 related articles for article (PubMed ID: 35119931)
1. Loss of
Huang Q; Li F; Hu H; Fang Z; Gao Z; Xia G; Ng WL; Khodadadi-Jamayran A; Chen T; Deng J; Zhang H; Almonte C; Labbe K; Han H; Geng K; Tang S; Freeman GJ; Li Y; Chen H; Wong KK
Sci Adv; 2022 Feb; 8(5):eabi9533. PubMed ID: 35119931
[TBL] [Abstract][Full Text] [Related]
2. TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.
Liu HJ; Lizotte PH; Du H; Speranza MC; Lam HC; Vaughan S; Alesi N; Wong KK; Freeman GJ; Sharpe AH; Henske EP
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669930
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.
Mrozek EM; Bajaj V; Guo Y; Malinowska IA; Zhang J; Kwiatkowski DJ
PLoS One; 2021; 16(4):e0248380. PubMed ID: 33891611
[TBL] [Abstract][Full Text] [Related]
4. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
5. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
[TBL] [Abstract][Full Text] [Related]
6. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
7. Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangioleiomyomatosis.
Maisel K; Merrilees MJ; Atochina-Vasserman EN; Lian L; Obraztsova K; Rue R; Vasserman AN; Zuo N; Angel LF; Gow AJ; Kang I; Wight TN; Eruslanov E; Swartz MA; Krymskaya VP
Am J Respir Cell Mol Biol; 2018 Dec; 59(6):723-732. PubMed ID: 30095976
[TBL] [Abstract][Full Text] [Related]
8. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.
Liang MC; Ma J; Chen L; Kozlowski P; Qin W; Li D; Goto J; Shimamura T; Hayes DN; Meyerson M; Kwiatkowski DJ; Wong KK
Oncogene; 2010 Mar; 29(11):1588-97. PubMed ID: 19966866
[TBL] [Abstract][Full Text] [Related]
9. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Genetic Analysis Results of TSC1/TSC2 Genes in Patients with Clinical Suspicion of Tuberous Sclerosis Complex and Definition of 3 Novel Variants.
Demir S; Yalçıntepe S; Atlı E; Yalçın Y; İkbal Atlı E; Eker D; Karal Y; Gürkan H
Balkan Med J; 2021 Nov; 38(6):341-347. PubMed ID: 34860161
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria.
Ye Q; Ling S; Jiang G; Shan Q; Xu S; Zhan Q; Wu Y; Liu Y; Zheng S; Xu X
Eur J Surg Oncol; 2021 Oct; 47(10):2533-2542. PubMed ID: 33902956
[TBL] [Abstract][Full Text] [Related]
13. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
16. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
[TBL] [Abstract][Full Text] [Related]
17. An Insight of Scientific Developments in TSC for Better Therapeutic Strategy.
Natarajan N; Thiruvenkatam V
Curr Top Med Chem; 2020; 20(23):2080-2093. PubMed ID: 32842942
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of TSC1 and TSC2 in Danish patients with tuberous sclerosis complex.
Rosengren T; Nanhoe S; de Almeida LGD; Schönewolf-Greulich B; Larsen LJ; Hey CAB; Dunø M; Ek J; Risom L; Nellist M; Møller LB
Sci Rep; 2020 Jun; 10(1):9909. PubMed ID: 32555378
[TBL] [Abstract][Full Text] [Related]
19. Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
Shirasawa M; Yoshida T; Shimoda Y; Takayanagi D; Shiraishi K; Kubo T; Mitani S; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Ichikawa H; Kohno T; Yamamoto N; Matsumoto S; Goto K; Watanabe SI; Ohe Y; Motoi N
J Thorac Oncol; 2021 Dec; 16(12):2078-2090. PubMed ID: 34419685
[TBL] [Abstract][Full Text] [Related]
20. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
Uruga H; Mino-Kenudson M
Virchows Arch; 2021 Jan; 478(1):31-44. PubMed ID: 33486574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
